PTPRE promotes gastric cancer cell resistance to 5-fluorouracil by inhibiting ferroptosis via the Src/FAK/TRIB3 axis
PLOS One · 18.06.2026 · 21 (6) · e0351846
DOI: 10.1371/journal.pone.0351846 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, online erschienen am 18.06.2026. Verfasst von Ming Liu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China. Hauptthemen laut MEDLINE: Stomach Neoplasms, Fluorouracil, Drug Resistance, Neoplasm, Ferroptosis. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Science Research Project of Hebei.
Abstract (Originalsprache)
Acquired drug resistance is a major cause of failure in gastric cancer treatment. The protein tyrosine phosphatase receptor type E (PTPRE) plays an oncogenic role in certain tumours; however, its function in chemotherapy-resistant gastric cancer remains unclear. Therefore, we analysed PTPRE expression in gastric cancer using The Cancer Genome Atlas. In vitro experiments were then conducted to investigate the effects of PTPRE on the resistance of cancer cells to 5-fluorouracil (5-FU) and its potential mechanisms. The results were further validated in vitro using xenograft studies. We found that PTPRE is upregulated in gastric cancer tissues and participates in the induction of 5-FU resistance. Mechanistic studies revealed that PTPRE suppressed ferroptosis in gastric cancer cells and promoted 5-FU resistance by activating the Src/FAK pathway to upregulate TRIB3 expression. In summary, PTPRE suppresses ferroptosis in gastric cancer cells via the Src/FAK/TRIB3 signalling pathway, thereby inducing 5-FU resistance. Intervention with PTPRE and its downstream targets may represent a potential approach for the clinical treatment of 5-FU-resistant gastric cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Radiation Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
- Department of Pain and Rehabilitation, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
- Department of Rheumatology and Immunology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
ORCID-Profile: Zhongkai Wang
Förderung
- Medical Science Research Project of Hebei
Zitieren
APA
Liu, M., Liao, X., Wang, F., Jiao, P., & Wang, Z. (2026). PTPRE promotes gastric cancer cell resistance to 5-fluorouracil by inhibiting ferroptosis via the Src/FAK/TRIB3 axis. PLOS One, 21(6), e0351846. https://doi.org/10.1371/journal.pone.0351846
Vancouver
Liu M, Liao X, Wang F, Jiao P, Wang Z. PTPRE promotes gastric cancer cell resistance to 5-fluorouracil by inhibiting ferroptosis via the Src/FAK/TRIB3 axis. PLOS One. 2026;21(6):e0351846. doi:10.1371/journal.pone.0351846
BibTeX
@article{Liu2026,
author = {Liu, Ming and Liao, Xiaomei and Wang, Fangchao and Jiao, Pengqing and Wang, Zhongkai},
title = {PTPRE promotes gastric cancer cell resistance to 5-fluorouracil by inhibiting ferroptosis via the Src/FAK/TRIB3 axis},
journal = {PLOS One},
year = {2026},
volume = {21},
number = {6},
pages = {e0351846},
doi = {10.1371/journal.pone.0351846}
}
EUVIMED